Literature DB >> 22325816

Epidemiological assessment of continuing transmission of lymphatic filariasis in Samoa.

H Joseph1, F Maiava, T Naseri, U Silva, P Lammie, W Melrose.   

Abstract

Ongoing transmission of lymphatic filariasis (LF) was assessed in five Samoan villages by measuring microfilaraemia (Mf), circulating filarial antigen (CFA) and antibody prevalence. Compared to the other villages, Fasitoo-Tai had a significantly higher Mf prevalence (3·2%), CFA prevalence (14·6%) and antibody prevalence in children (62·0%) (P<0·05). Puapua had a significantly lower CFA prevalence (2·5%), no detectable Mf-positive individuals and significantly low antibody prevalence in children (7·9%) (P<0·05). Siufaga, previously believed to be LF-free, recorded >1% CFA prevalence and a high antibody prevalence in children (46·6%). Overall, antibody prevalence in children appeared to reflect the transmission dynamics in the villages and, in Siufaga, identified an area of ongoing transmission. The Filariasis Cellabs Enzyme-Linked Immunosorbent Assay (CELISA), based on recombinant antigen Bm14, to detect antibodies, could potentially be a promising diagnostic tool for inclusion in future surveillance in the South Pacific.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22325816      PMCID： PMC4089807          DOI： 10.1179/2047773211Y.0000000008

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN： 0003-4983


  38 in total

1.  Evidence for the interruption of transmission of lymphatic filariasis among schoolchildren in Trinidad and Tobago.

Authors:  Samuel C Rawlins; Avril Siung-Chang; Shirematee Baboolal; Dave D Chadee
Journal:  Trans R Soc Trop Med Hyg       Date:  2004-08       Impact factor: 2.184

2.  Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.

Authors:  Daniel J Tisch; Moses J Bockarie; Zachary Dimber; Benson Kiniboro; Nandao Tarongka; Fred E Hazlett; Will Kastens; Michael P Alpers; James W Kazura
Journal:  Am J Trop Med Hyg       Date:  2008-02       Impact factor: 2.345

3.  Treatment failure in filariasis mass treatment programmes.

Authors:  L E Mahoney; J F Kessel
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

4.  Large-scale serological screening for cytomegalovirus antibodies in homosexual males by enzyme-linked immunosorbent assay.

Authors:  J S Dylewski; L Rasmussen; J Mills; T C Merigan
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

5.  A longitudinal study of Bancroftian filariasis in the Nile Delta of Egypt: baseline data and one-year follow-up.

Authors:  G J Weil; R M Ramzy; M El Setouhy; A M Kandil; E S Ahmed; R Faris
Journal:  Am J Trop Med Hyg       Date:  1999-07       Impact factor: 2.345

6.  Assessing transmission of lymphatic filariasis using parasitologic, serologic, and entomologic tools after mass drug administration in American Samoa.

Authors:  Janice M Mladonicky; Jonathan D King; Jennifer L Liang; Eric Chambers; Molisamoa Pa'au; Mark A Schmaedick; Thomas R Burkot; Mark Bradley; Patrick J Lammie
Journal:  Am J Trop Med Hyg       Date:  2009-05       Impact factor: 2.345

7.  Detection of filaria-specific IgG4 antibodies using Brugia Rapid test in individuals from an area highly endemic for Brugia timori.

Authors:  T Supali; N Rahmah; Y Djuardi; E Sartono; Paul Rückert; P Fischer
Journal:  Acta Trop       Date:  2004-05       Impact factor: 3.112

8.  Prolonged persistence of residual Wuchereria bancrofti infection after cessation of diethylcarbamazine-fortified salt programme.

Authors:  K D Ramaiah; B Thiruvengadam; P Vanamail; S Subramanian; S Gunasekaran; N Nilamani; P K Das
Journal:  Trop Med Int Health       Date:  2009-06-22       Impact factor: 2.622

Review 9.  Pacific collaboration to eliminate lymphatic filariasis.

Authors:  Kazuyo Ichimori; Andy Crump
Journal:  Trends Parasitol       Date:  2005-10

10.  Endpoints for lymphatic filariasis programs.

Authors:  Caroline A Grady; Madsen Beau de Rochars; Abdel N Direny; Jean Nicolas Orelus; Joyanna Wendt; Jeanne Radday; Els Mathieu; Jacquelin M Roberts; Thomas G Streit; David G Addiss; Patrick J Lammie
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883
View more
  16 in total

1.  Multiplex Serology for Measurement of IgG Antibodies Against Eleven Infectious Diseases in a National Serosurvey: Haiti 2014-2015.

Authors:  YuYen Chan; Diana Martin; Kimberly E Mace; Samuel E Jean; Gillian Stresman; Chris Drakeley; Michelle A Chang; Jean F Lemoine; Venkatachalam Udhayakumar; Patrick J Lammie; Jeffrey W Priest; Eric William Rogier
Journal:  Front Public Health       Date:  2022-06-09

2.  Genome-Scale Protein Microarray Comparison of Human Antibody Responses in Plasmodium vivax Relapse and Reinfection.

Authors:  Raul Chuquiyauri; Douglas M Molina; Eli L Moss; Ruobing Wang; Malcolm J Gardner; Kimberly C Brouwer; Sonia Torres; Robert H Gilman; Alejandro Llanos-Cuentas; Daniel E Neafsey; Philip Felgner; Xiaowu Liang; Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2015-07-06       Impact factor: 2.345

3.  Evaluation of traps and lures for mosquito vectors and xenomonitoring of Wuchereria bancrofti infection in a high prevalence Samoan Village.

Authors:  Limb K Hapairai; Catherine Plichart; Take Naseri; Ualesi Silva; Lameko Tesimale; Paulo Pemita; Hervé C Bossin; Thomas R Burkot; Scott A Ritchie; Patricia M Graves; Wayne Melrose; Hayley Joseph
Journal:  Parasit Vectors       Date:  2015-05-28       Impact factor: 3.876

4.  Diurnally subperiodic filariasis among the Nicobarese of Nicobar district - epidemiology, vector dynamics & prospects of elimination.

Authors:  A N Shriram; K Krishnamoorthy; P Vijayachari
Journal:  Indian J Med Res       Date:  2015-05       Impact factor: 2.375

5.  A practical strategy for responding to a case of lymphatic filariasis post-elimination in Pacific Islands.

Authors:  Humpress Harrington; James Asugeni; Christopher Jimuru; John Gwalaa; Elmer Ribeyro; Richard Bradbury; Hayley Joseph; Wayne Melrose; David MacLaren; Rick Speare
Journal:  Parasit Vectors       Date:  2013-07-26       Impact factor: 3.876

6.  Evaluation of the recombinant antigens Wb14 and WbT for the capture antibody diagnosis of lymphatic filariasis.

Authors:  André Filipe Pastor; Abraham Rocha; Klécia de Melo Cassemiro; Marli Tenório; Paula Melo; Maria Rosângela Grilis; Maressa Rhuama; Antonio Mauro Rezende; Osvaldo Pompilio de Melo Neto; Ernesto Marques; Rafael Dhalia
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-03-26       Impact factor: 2.743

7.  [Evaluation of the Filaria Detect™ IgG4 kit employing recombinant Wb123 antigen for diagnosis of lymphatic filariasis in BrazilEvaluación del estuche Detect™ para pruebas de anticuerpos antifiláricos IgG4, fabricado con el antígeno recombinante Wb123, para el diagnóstico de la filariasis linfática en Brasil].

Authors:  Paula Fernanda A S Melo; Maria Almerice L Silva; Maria Rosângela G Oliveira; Josué Araújo; Amanda Fernandes; George Tadeu N Diniz; Eduardo Brandão; Abraham Rocha; Maria Amélia Maciel
Journal:  Rev Panam Salud Publica       Date:  2021-07-08

8.  Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission.

Authors:  Paul E Simonsen; Yahya A Derua; William N Kisinza; Stephen M Magesa; Mwele N Malecela; Erling M Pedersen
Journal:  BMC Infect Dis       Date:  2013-07-21       Impact factor: 3.090

9.  Lymphatic filariasis in Luangwa District, South-East Zambia.

Authors:  Sheila Tamara Shawa; Enala T Mwase; Erling M Pedersen; Paul E Simonsen
Journal:  Parasit Vectors       Date:  2013-10-15       Impact factor: 3.876

10.  Assessment of lymphatic filariasis prior to re-starting mass drug administration campaigns in coastal Kenya.

Authors:  Sammy M Njenga; Henry M Kanyi; Faith M Mutungi; Collins Okoyo; Hadley S Matendechero; Rachel L Pullan; Katherine E Halliday; Simon J Brooker; C Njeri Wamae; Joyce K Onsongo; Kimberly Y Won
Journal:  Parasit Vectors       Date:  2017-02-22       Impact factor: 3.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.